top of page
  • Active, not recruiting

NCT01415882: Phase 2: Ixazomib Citrate in Relapsed Multiple Myeloma, Not Refractory to Bortezomib

Updated: Oct 4, 2022

NCT01415882: Phase 2: Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib

Ixazomib-dex- mayo clinic

NCT01415882: Phase 2: Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib


This phase II trial studies how well ixazomib citrate works in treating patients with multiple myeloma that has returned after a period of improvement (relapsed) but is not resistant to bortezomib (refractory). Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.


Sponsor

Mayo Clinic


Collaborator

National Cancer Institute (NCI)

 

ClinicalTrials.gov Identifier: NCT01415882

Official Title: Phase 2 Trial of Ixazomib Combinations in Patients With Relapsed Multiple Myeloma

First Posted : August 12, 2011

Click here to see details on ClinicalTrials.gov

 

Drug: Cyclophosphamide

Biological: Daratumumab

Drug: Dexamethasone

Drug: Ixazomib Citrate

Other: Laboratory Biomarker Analysis

 

Ixazomib: National Cancer Institute

Ixazomib: MedlinePlus Drug Information